For decades, the KRAS gene mutation sat at the center of pancreatic cancer research as a kind of taunt. It drives more than 90% of cases. Its surface is smooth, offering nothing for a drug to grab. Scientists called it undruggable. Patients died.
That history makes the numbers from a new Phase 3 trial land differently. An experimental pill called daraxonrasib nearly doubled survival in patients with advanced pancreatic cancer who had already been through prior treatment. Median survival hit 13.2 months on the drug. Standard chemotherapy gave those patients 6.7 months. That is a 60% reduction in the risk of death.
The drug works by an unusual mechanism. It grabs a helper molecule inside cells called cyclophilin A. That complex then clamps onto active KRAS and shuts down its growth signal. The approach targets multiple RAS mutations at once, which makes it harder for cancer cells to develop resistance. That is a key difference from earlier attempts that failed because the cancer found a workaround.
The trial enrolled 500 patients with metastatic pancreatic cancer. Results were published in the New England Journal of Medicine. Revolution Medicines developed the drug. The company has released the data. Regulatory approval has not yet been granted.
Side effects are real. Most patients developed a skin rash. Mouth sores, diarrhea, and nausea were common. But researchers reported these effects were manageable. Patients on daraxonrasib were less likely to stop treatment than those on chemotherapy. They also reported better quality of life. That last point matters in a disease where treatment can feel as punishing as the cancer itself.
Pancreatic cancer has a grim reputation for a reason. It is often caught late. It spreads fast. Standard treatments buy months, not years. New options have been rare. Experts quoted in the trial report describe daraxonrasib as potentially the most significant advance in pancreatic cancer treatment in a generation. That is not a phrase doctors use lightly for this disease.
The background matters here. KRAS was discovered as an oncogene in the early 1980s. For nearly four decades, it defeated every attempt at direct targeting. The protein’s surface lacks deep pockets where small molecules can bind. Drug developers tried. They failed. Then came a breakthrough in 2013 with a compound that targeted a specific KRAS mutation called G12C. That opened the door for lung cancer treatments. But pancreatic cancer is driven mostly by a different mutation, G12D, and by others that the G12C drugs cannot touch.
Daraxonrasib sidesteps that limitation. By using cyclophilin A as an intermediary, it can bind to multiple active forms of KRAS. That breadth is what makes the trial results significant. It is not a fix for every patient, but it covers a much larger share of the pancreatic cancer population than any previous targeted therapy.
The trial enrolled only patients who had already received prior treatment. That is a tough group. Their cancer had already proven it could survive standard therapy. The survival gain in that population is what gives the drug its weight. The next question is whether it works earlier in the disease, before the cancer has had time to adapt.
For now, the data provides what the field has lacked: a concrete signal that KRAS can be targeted in pancreatic cancer with a meaningful result. The drug still needs approval. The side effects need management in real-world practice. But the mechanism has been demonstrated. The wall that stood for forty years has a crack in it.
